StockNews.com Begins Coverage on Regulus Therapeutics (NASDAQ:RGLS)

StockNews.com assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other research firms have also commented on RGLS. HC Wainwright reaffirmed a buy rating and set a $9.00 price objective on shares of Regulus Therapeutics in a research note on Monday, March 25th. SVB Leerink began coverage on Regulus Therapeutics in a research report on Monday, March 18th. They set an outperform rating and a $6.00 target price on the stock. Canaccord Genuity Group reduced their target price on Regulus Therapeutics from $12.00 to $11.00 and set a buy rating on the stock in a research report on Tuesday, March 19th. Leerink Partnrs reiterated an outperform rating on shares of Regulus Therapeutics in a research report on Monday, March 18th. Finally, Wells Fargo & Company increased their target price on Regulus Therapeutics from $2.00 to $3.00 and gave the stock an equal weight rating in a research report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Regulus Therapeutics has an average rating of Moderate Buy and a consensus price target of $7.25.

Regulus Therapeutics Stock Performance

Regulus Therapeutics stock opened at $2.56 on Tuesday. The firm has a market capitalization of $167.58 million, a price-to-earnings ratio of -1.61 and a beta of 1.56. Regulus Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $3.79. The stock’s fifty day moving average is $2.06 and its two-hundred day moving average is $1.58.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported ($0.40) EPS for the quarter, meeting analysts’ consensus estimates of ($0.40). As a group, sell-side analysts forecast that Regulus Therapeutics will post -0.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

Large investors have recently modified their holdings of the company. FMR LLC raised its holdings in shares of Regulus Therapeutics by 32.4% in the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock worth $4,033,000 after purchasing an additional 716,000 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Regulus Therapeutics by 5.3% in the 3rd quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company’s stock worth $322,000 after purchasing an additional 11,701 shares during the period. Federated Hermes Inc. purchased a new position in shares of Regulus Therapeutics in the 1st quarter worth about $8,656,000. Vanguard Group Inc. raised its holdings in shares of Regulus Therapeutics by 21.4% during the 1st quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 648,121 shares during the period. Finally, Exome Asset Management LLC purchased a new stake in shares of Regulus Therapeutics during the 4th quarter valued at about $228,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.